Moreover, VWF release can be triggered at the sites of vascular injury or by desmopressin (DDAVP), which is used as a treatment for mild hemophilia A and von Willebrand disease [52,57], which is the most prevalent congenital bleeding disorder that arises from deficiencies in quantity or quality of von Willebrand factor (VWF). The gene discussed is VWF; the disease is platelet-type von Willebrand disease.